Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 369

1.

Age-associated mRNA expression changes in bovine endometrial cells in vitro.

Tanikawa N, Ohtsu A, Kawahara-Miki R, Kimura K, Matsuyama S, Iwata H, Kuwayama T, Shirasuna K.

Reprod Biol Endocrinol. 2017 Aug 14;15(1):63. doi: 10.1186/s12958-017-0284-z.

2.

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Nomura S, Doi T, Sato A, Ohtsu A, Yoshino T.

Lancet Oncol. 2017 Jul 28. pii: S1470-2045(17)30425-4. doi: 10.1016/S1470-2045(17)30425-4. [Epub ahead of print]

PMID:
28760399
3.

Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma.

Hatogai K, Fujii S, Kojima T, Daiko H, Nomura S, Doi T, Kitano S, Ohtsu A, Takiguchi Y, Yoshino T, Ochiai A.

J Cancer Res Clin Oncol. 2017 Jul 29. doi: 10.1007/s00432-017-2482-7. [Epub ahead of print]

PMID:
28756492
4.

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.

Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS.

Mol Cancer Ther. 2017 Jul 17. pii: molcanther.0895.2016. doi: 10.1158/1535-7163.MCT-16-0895. [Epub ahead of print]

PMID:
28716815
5.

Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.

Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, Ito S, Ohtsu A, Koike M, Murayama K, Moriya K, Tamura H, Matsumoto M, Nakahashi H, Tanosaki S, Sakura T, Kawamura T, Miyanaga T, Nakamura N, Murakami H, Handa H, Tsukamoto N.

Int J Hematol. 2017 Jul 7. doi: 10.1007/s12185-017-2297-y. [Epub ahead of print]

PMID:
28687991
6.

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.

Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, Safran H, Bodoky G, Chau I, Shimada Y, Al-Batran SE, Passalacqua R, Ohtsu A, Emig M, Ferry D, Chandrawansa K, Hsu Y, Sashegyi A, Liepa AM, Wilke H.

J Gastric Cancer. 2017 Jun;17(2):132-144. doi: 10.5230/jgc.2017.17.e16. Epub 2017 Jun 16.

7.

Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.

Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A.

Gastric Cancer. 2017 Jun 20. doi: 10.1007/s10120-017-0737-2. [Epub ahead of print]

PMID:
28634748
8.

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).

Shitara K, Doi T, Nagano O, Fukutani M, Hasegawa H, Nomura S, Sato A, Kuwata T, Asai K, Einaga Y, Tsuchihashi K, Suina K, Maeda Y, Saya H, Ohtsu A.

Gastric Cancer. 2017 May 2. doi: 10.1007/s10120-017-0720-y. [Epub ahead of print]

PMID:
28466360
9.

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK.

Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23.

PMID:
28343975
10.

Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A).

Nomura M, Kato K, Ando N, Ohtsu A, Muro K, Igaki H, Abe T, Takeuchi H, Daiko H, Gotoh M, Kataoka K, Wakabayashi M, Kitagawa Y.

Jpn J Clin Oncol. 2017 Jun 1;47(6):480-486. doi: 10.1093/jjco/hyx040.

PMID:
28334858
11.

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Kitagawa Y.

Lancet Oncol. 2017 May;18(5):631-639. doi: 10.1016/S1470-2045(17)30181-X. Epub 2017 Mar 15.

PMID:
28314688
12.

Clinical impact of surveillance for head and neck cancer in patients with esophageal squamous cell carcinoma.

Morimoto H, Yano T, Yoda Y, Oono Y, Ikematsu H, Hayashi R, Ohtsu A, Kaneko K.

World J Gastroenterol. 2017 Feb 14;23(6):1051-1058. doi: 10.3748/wjg.v23.i6.1051.

13.

NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis.

Doi T, Hamaguchi T, Shitara K, Iwasa S, Shimada Y, Harada M, Naito K, Hayashi N, Masada A, Ohtsu A.

Cancer Chemother Pharmacol. 2017 Mar;79(3):569-578. doi: 10.1007/s00280-017-3254-4. Epub 2017 Feb 21.

14.

Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials.

Noguchi S, Shinohara N, Ito T, Ohtsu A, Ravaud A, Jerusalem G, Ohno N, Gallo J, Bouillaud E, Fan J, Nonomura N.

Oncology. 2017;92(5):243-254. doi: 10.1159/000457904. Epub 2017 Feb 21.

PMID:
28219073
15.

Palmitic acid stimulates interleukin-8 via the TLR4/NF-κB/ROS pathway and induces mitochondrial dysfunction in bovine oviduct epithelial cells.

Ohtsu A, Tanaka H, Seno K, Iwata H, Kuwayama T, Shirasuna K.

Am J Reprod Immunol. 2017 Jun;77(6). doi: 10.1111/aji.12642. Epub 2017 Feb 10.

PMID:
28185389
16.

Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib.

Doi A, Kuboki Y, Shitara K, Fukuoka S, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T.

Clin Colorectal Cancer. 2016 Dec 28. pii: S1533-0028(16)30257-2. doi: 10.1016/j.clcc.2016.11.003. [Epub ahead of print] No abstract available.

17.

Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.

Hatogai K, Fujii S, Kojima T, Daiko H, Doi T, Ohtsu A, Ochiai A, Takiguchi Y, Yoshino T.

BMC Cancer. 2017 Jan 9;17(1):36. doi: 10.1186/s12885-016-3041-3.

18.

Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.

Fukuoka S, Kojima T, Koga Y, Yamauchi M, Komatsu M, Komatsuzaki R, Sasaki H, Yasunaga M, Matsumura Y, Doi T, Ohtsu A.

Oncotarget. 2017 Feb 14;8(7):11020-11029. doi: 10.18632/oncotarget.14209.

19.

Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma.

Kadota T, Yano T, Kato T, Imajoh M, Noguchi M, Morimoto H, Osera S, Yoda Y, Oono Y, Ikematsu H, Ohtsu A, Kaneko K.

Endosc Int Open. 2016 Dec;4(12):E1267-E1274. doi: 10.1055/s-0042-118291. Epub 2016 Nov 21.

20.

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.

Doi T, Fuse N, Yoshino T, Kojima T, Bando H, Miyamoto H, Kaneko M, Osada M, Ohtsu A.

Cancer Chemother Pharmacol. 2017 Jan;79(1):89-98. doi: 10.1007/s00280-016-3198-0. Epub 2016 Dec 3.

Supplemental Content

Loading ...
Support Center